Hikma, MPP sign licensing agreement for COVID-19 pill

[20-01-2022 06:39 PM]

Ammon News - Hikma Pharmaceuticals signed a licensing agreement with the Medicines Patent Pool (MPP) to manufacture and market Molnupiravir, an oral antiviral medicine for the treatment of mild-to-moderate COVID-19 in adults.

In a statement on Thursday, the company said that the agreement aims at enhancing patients' access to one of the most important drugs used to treat the coronavirus, developed by Merck, an American multinational pharmaceutical company, and to place it on the markets of the Middle East and North Africa.

Under the agreement, Hikma has the rights to use Merck's patents and manufacturing expertise for the drug, and is responsible for manufacturing and marketing the product in 105 low- and middle-income countries in the Middle East.

Executive Vice Chairman and President of Hikma in the Middle East and North Africa Mazen Darwazah said that the agreement comes in line with the company's mission to provide better health for all, and to facilitate the access for Molnupiravir use in low- and middle-income countries.

The agreement, he explained, reflects Hikma's ongoing commitment to improving access to high-quality and affordable treatments, adding that the company is "looking forward to providing and enabling patients to use this treatment soon."

  • no comments

All comments are reviewed and posted only if approved.
Ammon News reserves the right to delete any comment at any time, and for any reason, and will not publish any comment containing offense or deviating from the subject at hand, or to include the names of any personalities or to stir up sectarian, sectarian or racial strife, hoping to adhere to a high level of the comments as they express The extent of the progress and culture of Ammon News' visitors, noting that the comments are expressed only by the owners.
name : *
show email
comment : *
Verification code : Refresh
write code :